Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis and Zealand Pharma have gained some ammunition as they prepare to enter the competitive GLP-1 agonist market, with data from a head-to-head study showing their lixisenatide to be non-inferior to Lilly/Amylin's Byetta (exenatide).
You may also be interested in...
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
If FDA approves the new protocol, a QT prolongation study required to refile Bydureon could commence this quarter.
Sanofi's Lixisenatide/Lantus Combo Could Be A Critical Growth Driver
During business update, French pharma outlines market of 9 million potential patients for the drug combo.